Amicus Therapeutics (FOLD) Financials

$6.22 -0.04 (-0.64%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$6.31 +0.09 (+1.43%)

As of 05/23/2025 06:00 PM Eastern

Annual Income Statements for Amicus Therapeutics

This table shows Amicus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-56	-152	-237	-250	-277	-356	-284	-200	-132
Consolidated Net Income / (Loss)	-56	-152	-237	-250	-277	-356	-284	-200	-132
Net Income / (Loss) Continuing Operations	-56	-152	-237	-250	-277	-356	-284	-200	-132
Total Pre-Tax Income	-29	-150	-242	-242	-274	-356	-449	-204	-132
Total Operating Income	25	-77	-212	-206	-247	-304	-442	-182	-130
Total Gross Profit	475	362	291	271	230	160	31	4.13	0.00
Total Revenue	528	399	329	306	261	182	37	4.96	0.00
Operating Revenue	528	399	329	306	261	182	37	4.96	-
Total Cost of Revenue	53	37	39	34	31	22	6.24	0.83	0.00
Operating Cost of Revenue	53	37	39	34	31	22	6.24	0.83	-
Total Operating Expenses	450	439	503	478	477	464	473	186	130
Selling, General & Admin Expense	323	275	213	193	156	170	89	71	47
Research & Development Expense	109	152	277	272	308	286	149	105	77
Depreciation Expense	8.55	7.87	5.34	6.21	8.85	4.78	3.59	3.24	1.83
Other Operating Expenses / (Income)	0.00	-	0.00	0.26	-	0.00	0.00	-	-
Impairment Charge	0.00	1.13	6.62	0.00	0.00	-	465	0.00	-
Restructuring Charge	9.19	0.00	0.00	-	-	-	-	0.07	0.02
Other Special Charges / (Income)	0.00	2.58	1.08	6.51	3.14	3.30	-234	6.76	4.38
Total Other Income / (Expense), net	-54	-73	-30	-35	-27	-52	-7.14	-22	-1.68
Interest Expense	50	64	37	32	22	19	17	5.40	1.58
Interest & Investment Income	5.41	7.08	3.02	0.51	3.23	10	4.10	1.60	0.93
Other Income / (Expense), net	-9.44	-16	4.18	-2.90	-8.06	-43	6.01	-18	-1.03
Income Tax Expense	27	1.48	-5.47	8.91	2.60	0.48	-165	-3.74	-
Basic Earnings per Share	($0.18)	($0.51)	($0.82)	($0.92)	($1.07)	($1.48)	($1.85)	($1.49)	($1.20)
Weighted Average Basic Shares Outstanding	304.38M	295.16M	289.06M	271.42M	258.87M	240.42M	153.36M	134.40M	109.92M
Diluted Earnings per Share	($0.18)	($0.51)	($0.82)	($0.92)	($1.07)	($1.48)	($1.85)	($1.49)	($1.20)
Weighted Average Diluted Shares Outstanding	304.38M	295.16M	289.06M	271.42M	258.87M	240.42M	153.36M	134.40M	109.92M
Weighted Average Basic & Diluted Shares Outstanding	300.12M	295.38M	282.71M	280.03M	258.87M	240.42M	153.36M	134.40M	109.92M

This table shows Amicus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-22	15	-6.73	-16	-48	-34	-22	-43	-53	-56	-33
Consolidated Net Income / (Loss)	-22	15	-6.73	-16	-48	-34	-22	-43	-53	-56	-33
Net Income / (Loss) Continuing Operations	-22	15	-6.73	-16	-48	-34	-22	-43	-53	-56	-33
Total Pre-Tax Income	-18	7.93	6.79	0.11	-44	-32	-25	-41	-53	-70	-29
Total Operating Income	-7.95	16	22	15	-28	-3.69	-17	-19	-38	-42	-34
Total Gross Profit	114	135	128	115	97	104	94	85	79	79	68
Total Revenue	125	150	142	127	110	115	104	95	86	88	82
Operating Revenue	125	150	142	127	110	115	104	95	86	88	82
Total Cost of Revenue	12	15	13	11	14	11	9.95	9.11	6.94	9.38	13
Operating Cost of Revenue	12	15	13	11	14	11	9.95	9.11	6.94	9.38	13
Total Operating Expenses	122	119	107	100	125	108	111	104	117	121	102
Selling, General & Admin Expense	92	87	75	74	88	70	66	65	74	54	47
Research & Development Expense	28	30	26	25	28	35	41	35	41	64	53
Depreciation Expense	1.84	2.04	2.17	2.18	2.15	2.18	2.23	2.21	1.26	1.31	1.29
Restructuring Charge	0.00	-	3.14	0.00	6.05	-	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	-10	-8.04	-15	-15	-16	-28	-7.68	-22	-16	-28	4.58
Interest Expense	11	12	13	13	12	27	13	12	12	11	9.62
Interest & Investment Income	0.81	1.42	1.08	1.37	1.54	1.67	1.47	1.74	2.20	1.97	0.56
Other Income / (Expense), net	0.55	2.51	-3.26	-3.72	-4.97	-2.63	3.83	-11	-6.19	-19	14
Income Tax Expense	3.64	-6.81	14	16	4.84	2.18	-3.13	2.72	-0.29	-14	4.02
Basic Earnings per Share	($0.07)	$0.05	($0.02)	($0.05)	($0.16)	($0.11)	($0.07)	($0.15)	($0.18)	($0.19)	($0.12)
Weighted Average Basic Shares Outstanding	307.69M	304.38M	304.69M	303.77M	302.90M	295.16M	295.76M	292.80M	291.34M	289.06M	289.22M
Diluted Earnings per Share	($0.07)	$0.05	($0.02)	($0.05)	($0.16)	($0.11)	($0.07)	($0.15)	($0.18)	($0.19)	($0.12)
Weighted Average Diluted Shares Outstanding	307.69M	304.38M	304.69M	303.77M	302.90M	295.16M	295.76M	292.80M	291.34M	289.06M	289.22M
Weighted Average Basic & Diluted Shares Outstanding	307.93M	300.12M	298.81M	296.59M	296.20M	295.38M	293.25M	287.12M	284.58M	282.71M	280.95M

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-33	97	-96	83	20	64	30	-136	118	45
Net Cash From Operating Activities	-34	-69	-167	-202	-233	-250	-300	-214	-150	-100
Net Cash From Continuing Operating Activities	-34	-69	-167	-202	-233	-249	-300	-214	-150	-100
Net Income / (Loss) Continuing Operations	-56	-152	-237	-250	-277	-356	-349	-284	-200	-132
Consolidated Net Income / (Loss)	-56	-152	-237	-250	-277	-356	-349	-284	-200	-132
Depreciation Expense	8.55	7.87	5.34	6.21	8.85	4.78	4.22	3.59	3.24	1.83
Amortization Expense	2.26	2.62	2.63	2.49	1.79	2.55	11	9.70	2.69	-
Non-Cash Adjustments To Reconcile Net Income	110	101	101	51	62	85	35	483	39	11
Changes in Operating Assets and Liabilities, net	-99	-29	-39	-12	-29	15	-1.43	-426	4.81	19
Net Cash From Investing Activities	-0.56	98	92	79	-14	95	-121	-171	-4.51	-145
Net Cash From Continuing Investing Activities	-0.56	98	92	79	-14	95	-121	-171	-4.51	-145
Purchase of Property, Plant & Equipment	-3.55	-7.44	-3.77	-3.88	-3.23	-20	-6.31	-4.53	-5.95	-4.82
Purchase of Investments	-115	-92	-243	-341	-365	-384	-578	-490	-220	-290
Sale of Property, Plant & Equipment	0.00	0.00	3.41	0.00	0.00	-	-	-	-	-
Sale and/or Maturity of Investments	118	197	336	424	355	499	464	324	221	290
Net Cash From Financing Activities	5.12	62	-7.46	212	263	218	451	247	273	291
Net Cash From Continuing Financing Activities	5.12	62	-7.46	212	263	218	451	247	273	291
Repayment of Debt	0.00	-408	0.00	0.00	-155	0.00	0.00	-0.31	-80	-15
Issuance of Debt	0.00	387	0.00	0.00	386	0.00	147	0.00	273	50
Issuance of Common Equity	20	63	0.00	0.00	0.00	189	295	243	97	243
Other Financing Activities, net	-14	19	-7.46	212	32	32	12	6.30	-15	15
Effect of Exchange Rate Changes	-4.03	-	-	-5.05	-	-	-	-	-	-
Cash Interest Paid	59	36	34	30	25	17	7.50	7.42	2.99	0.61
Cash Income Taxes Paid	8.21	8.53	1.61	20	10	0.69	1.06	-	-	-

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-32	-20	24	-0.44	-37	-16	52	49	12	-128	42
Net Cash From Operating Activities	7.76	-3.92	-23	23	-30	3.46	-38	-16	-18	-81	-12
Net Cash From Continuing Operating Activities	7.76	-3.92	-23	23	-30	3.46	-38	-16	-18	-81	-12
Net Income / (Loss) Continuing Operations	-22	15	-6.73	-16	-48	-34	-22	-43	-53	-56	-33
Consolidated Net Income / (Loss)	-22	15	-6.73	-16	-48	-34	-22	-43	-53	-56	-33
Depreciation Expense	1.84	2.04	2.17	2.18	2.15	2.18	2.23	2.21	1.26	1.31	1.29
Amortization Expense	0.61	0.60	0.57	0.56	0.53	0.54	0.72	0.69	0.67	0.67	0.67
Non-Cash Adjustments To Reconcile Net Income	21	22	25	25	38	20	11	29	41	23	22
Changes in Operating Assets and Liabilities, net	6.01	-44	-44	11	-22	14	-31	-4.52	-7.84	-50	-2.55
Net Cash From Investing Activities	-33	-20	34	-22	7.54	-24	36	50	36	-67	75
Net Cash From Continuing Investing Activities	-33	-20	34	-22	7.54	-24	36	50	36	-67	75
Purchase of Property, Plant & Equipment	-0.21	-0.29	-0.36	-1.10	-1.81	-1.73	-1.57	-2.20	-1.94	-2.68	0.14
Purchase of Investments	-39	-36	-4.91	-44	-30	-39	-17	-20	-17	-143	-1.48
Sale and/or Maturity of Investments	6.16	16	40	23	39	16	54	72	55	76	76
Net Cash From Financing Activities	-12	1.10	18	-0.86	-13	8.21	38	24	-7.83	0.56	-0.56
Net Cash From Continuing Financing Activities	-12	1.10	18	-0.86	-13	8.21	38	24	-7.83	0.56	-0.56
Other Financing Activities, net	-12	0.68	-0.96	-0.86	-13	29	1.06	-0.53	-10	0.56	-0.56
Other Net Changes in Cash	4.82	-	-	-	-	-3.91	17	-8.19	1.51	19	-
Cash Interest Paid	11	11	24	12	12	0.64	12	12	11	10	8.95
Cash Income Taxes Paid	0.38	5.49	1.60	0.49	0.64	2.05	0.50	5.80	0.18	0.67	0.23

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	785	778	724	905	887	850	790	627	1,037	908
Total Current Assets	505	483	424	597	579	520	551	392	340	217
Cash & Equivalents	214	247	149	245	163	143	80	49	187	69
Short-Term Investments	36	39	145	237	320	310	424	310	143	145
Accounts Receivable	101	88	66	53	47	33	22	9.46	1.30	-
Inventories, net	119	60	24	27	20	14	8.39	4.62	3.42	0.00
Prepaid Expenses	35	50	40	35	30	20	17	19	4.99	2.57
Plant, Property, & Equipment, net	29	32	31	42	44	48	11	9.06	9.82	6.18
Total Noncurrent Assets	251	263	270	266	263	282	227	226	687	686
Goodwill	198	198	198	198	198	198	198	198	198	198
Intangible Assets	17	20	23	23	23	23	23	23	487	487
Other Noncurrent Operating Assets	36	45	49	45	42	62	6.68	5.20	2.47	1.11
Total Liabilities & Shareholders' Equity	785	778	724	905	887	850	790	627	1,037	908
Total Liabilities	591	618	601	598	600	374	447	274	677	561
Total Current Liabilities	149	168	139	146	130	129	86	70	111	74
Accounts Payable	13	15	15	22	17	22	81	54	41	32
Accrued Expenses	127	144	94	98	97	100	-	-	-	-
Other Current Liabilities	8.46	8.32	8.55	7.41	6.87	7.19	-	-	-	-
Total Noncurrent Liabilities	442	450	462	452	470	245	361	204	566	487
Long-Term Debt	390	388	392	389	389	150	322	164	154	-
Other Noncurrent Operating Liabilities	52	62	70	52	69	82	23	19	216	233
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	194	160	123	307	286	476	343	353	360	348
Total Preferred & Common Equity	194	160	123	307	286	476	343	353	360	348
Total Common Equity	194	160	123	307	286	476	343	353	360	348
Common Stock	2,929	2,839	2,668	2,598	2,311	2,230	1,742	1,402	1,122	919
Retained Earnings	-2,740	-2,684	-2,532	-2,296	-2,045	-1,769	-1,412	-1,064	-780	-580
Accumulated Other Comprehensive Income / (Loss)	5.10	5.24	-12	4.98	8.23	2.83	0.07	-2.10	2.05	-0.12
Other Equity Adjustments	0.07	0.07	0.08	0.08	12	12	13	16	16	8.76

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	790	787	749	722	764	730	701	760
Total Current Assets	511	498	462	431	463	433	400	459
Cash & Equivalents	182	234	209	210	263	211	161	278
Short-Term Investments	69	16	51	30	17	54	107	77
Accounts Receivable	88	98	85	76	73	64	68	52
Inventories, net	132	115	81	61	57	51	27	13
Prepaid Expenses	39	35	35	54	53	52	37	38
Plant, Property, & Equipment, net	29	30	31	32	31	30	31	32
Total Noncurrent Assets	250	258	257	258	270	267	269	269
Goodwill	198	198	198	198	198	198	198	198
Intangible Assets	16	18	19	20	21	22	23	23
Other Noncurrent Operating Assets	36	42	40	41	51	47	49	48
Total Liabilities & Shareholders' Equity	790	787	749	722	764	730	701	760
Total Liabilities	596	608	617	591	631	619	598	627
Total Current Liabilities	153	158	168	142	169	159	138	165
Accounts Payable	14	13	32	9.21	23	14	25	12
Accrued Expenses	130	136	128	125	139	125	93	125
Other Current Liabilities	8.56	8.54	8.11	8.27	7.77	7.84	8.01	7.54
Total Noncurrent Liabilities	443	450	449	449	461	459	460	462
Long-Term Debt	391	389	389	388	394	393	393	391
Other Noncurrent Operating Liabilities	53	60	60	61	61	60	61	60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	194	179	133	131	133	112	103	133
Total Preferred & Common Equity	194	179	133	131	133	112	103	133
Total Common Equity	194	179	133	131	133	112	103	133
Common Stock	2,943	2,909	2,872	2,856	2,790	2,736	2,695	2,648
Retained Earnings	-2,762	-2,755	-2,748	-2,732	-2,650	-2,629	-2,585	-2,477
Treasury Stock	-0.07	-	-	-	-	-	-	-
Accumulated Other Comprehensive Income / (Loss)	13	25	8.79	6.64	-6.77	4.16	-6.74	-39
Other Equity Adjustments	0.00	0.07	0.07	0.07	0.07	0.07	0.08	0.08

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	32.29%	21.30%	7.76%	17.11%	43.16%	0.00%	0.00%	644.86%	0.00%	-100.00%
EBITDA Growth	131.77%	58.69%	0.33%	17.91%	28.11%	-5.59%	23.83%	-117.82%	-49.69%	-92.82%
EBIT Growth	116.58%	55.23%	0.66%	17.93%	26.56%	-3.01%	22.67%	-118.00%	-52.12%	-91.15%
NOPAT Growth	132.22%	63.60%	-2.75%	16.42%	18.76%	7.52%	17.66%	-143.00%	-39.45%	-89.86%
Net Income Growth	62.99%	35.92%	5.55%	9.53%	22.32%	-2.12%	-22.88%	-41.97%	-51.41%	-91.68%
EPS Growth	64.71%	37.80%	10.87%	14.02%	27.70%	0.00%	0.00%	-24.16%	-24.17%	-29.03%
Operating Cash Flow Growth	50.95%	58.52%	17.74%	13.20%	6.84%	16.52%	-40.37%	-42.32%	-49.94%	-93.81%
Free Cash Flow Firm Growth	24.73%	53.85%	10.29%	12.24%	10.88%	-0.77%	-8.64%	-56.33%	55.72%	-814.54%
Invested Capital Growth	27.64%	7.81%	4.17%	15.83%	16.21%	7.91%	-3.81%	-30.58%	10.87%	764.81%
Revenue Q/Q Growth	7.01%	7.25%	1.84%	3.94%	6.22%	0.00%	0.00%	47.53%	133.10%	-100.00%
EBITDA Q/Q Growth	1,617.54%	40.13%	5.30%	-0.23%	8.05%	-7.56%	-1.30%	-3.55%	-10.91%	-18.47%
EBIT Q/Q Growth	264.89%	36.98%	5.18%	0.29%	7.26%	-6.55%	-1.44%	-3.87%	-12.43%	-18.39%
NOPAT Q/Q Growth	377.19%	33.35%	12.32%	-3.67%	8.92%	-6.87%	-0.55%	-5.31%	-2.26%	-17.46%
Net Income Q/Q Growth	46.41%	12.69%	10.38%	-4.98%	6.21%	-3.38%	-2.61%	-3.86%	-8.55%	-20.12%
EPS Q/Q Growth	47.06%	13.56%	10.87%	-2.22%	4.46%	6.92%	0.00%	-1.09%	-3.47%	-11.11%
Operating Cash Flow Q/Q Growth	-27.81%	54.94%	-6.56%	-11.38%	3.32%	1.12%	3.96%	-24.05%	2.54%	-26.54%
Free Cash Flow Firm Q/Q Growth	19.06%	47.50%	-18.97%	-6.89%	2.57%	-8.26%	10.55%	-17.64%	19.98%	-18.53%
Invested Capital Q/Q Growth	4.91%	6.00%	28.49%	3.44%	0.75%	-5.53%	-7.85%	9.14%	-2.36%	19.04%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.98%	90.65%	88.28%	88.72%	88.10%	87.95%	0.00%	83.11%	83.20%	0.00%
EBITDA Margin	4.97%	-20.69%	-60.74%	-65.67%	-93.69%	-186.55%	0.00%	-1,144.55%	-3,913.96%	0.00%
Operating Margin	4.71%	-19.33%	-64.43%	-67.57%	-94.68%	-166.84%	0.00%	-1,196.82%	-3,668.62%	0.00%
EBIT Margin	2.92%	-23.31%	-63.16%	-68.52%	-97.76%	-190.57%	0.00%	-1,180.55%	-4,033.58%	0.00%
Profit (Net Income) Margin	-10.62%	-37.96%	-71.85%	-81.98%	-106.12%	-195.56%	0.00%	-769.03%	-4,034.73%	0.00%
Tax Burden Percent	195.11%	100.99%	97.74%	103.69%	100.95%	100.13%	99.97%	63.24%	98.17%	100.00%
Interest Burden Percent	-186.30%	161.23%	116.40%	115.39%	107.53%	102.48%	103.54%	103.01%	101.90%	100.49%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	5.84%	-21.42%	-62.39%	-66.53%	-92.35%	-127.56%	0.00%	-151.95%	-55.70%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-54.96%	-109.50%	-448.95%	66.45%	-38.81%	-68.44%	0.00%	-168.56%	2.28%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-37.52%	-85.62%	-47.54%	-17.83%	19.76%	40.56%	0.00%	72.29%	-0.81%	0.00%
Return on Equity (ROE)	-31.68%	-107.04%	-109.93%	-84.37%	-72.59%	-86.99%	-100.32%	-79.66%	-56.51%	-56.22%
Cash Return on Invested Capital (CROIC)	-18.44%	-28.94%	-66.48%	-81.20%	-107.34%	-135.16%	-136.72%	-115.85%	-66.01%	-157.16%
Operating Return on Assets (OROA)	1.98%	-12.40%	-25.53%	-23.37%	-29.37%	-42.35%	0.00%	-52.41%	-20.56%	0.00%
Return on Assets (ROA)	-7.18%	-20.18%	-29.04%	-27.96%	-31.88%	-43.46%	0.00%	-34.14%	-20.57%	0.00%
Return on Common Equity (ROCE)	-31.68%	-107.04%	-109.93%	-84.37%	-72.59%	-86.99%	-100.32%	-79.66%	-56.51%	-56.22%
Return on Equity Simple (ROE_SIMPLE)	-28.91%	-94.64%	-192.26%	-81.49%	-96.67%	-74.80%	-101.77%	-80.49%	-55.54%	-37.98%
Net Operating Profit after Tax (NOPAT)	17	-54	-148	-145	-173	-213	-230	-309	-127	-91
NOPAT Margin	3.30%	-13.53%	-45.10%	-47.30%	-66.27%	-116.79%	0.00%	-837.77%	-2,568.03%	0.00%
Net Nonoperating Expense Percent (NNEP)	60.80%	88.08%	386.56%	-132.98%	-53.54%	-59.12%	-64.52%	16.61%	-57.99%	-28.56%
Return On Investment Capital (ROIC_SIMPLE)	2.98%	-9.86%	-27.68%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	10.02%	9.35%	11.72%	11.28%	11.90%	12.05%	0.00%	16.89%	16.80%	0.00%
SG&A Expenses to Revenue	61.21%	68.93%	64.71%	63.08%	59.95%	93.21%	0.00%	240.11%	1,435.07%	0.00%
R&D to Revenue	20.70%	38.16%	84.04%	89.05%	118.23%	157.15%	0.00%	404.31%	2,113.61%	0.00%
Operating Expenses to Revenue	85.27%	109.99%	152.70%	156.37%	182.78%	254.78%	0.00%	1,279.93%	3,751.82%	0.00%
Earnings before Interest and Taxes (EBIT)	15	-93	-208	-209	-255	-347	-337	-436	-200	-131
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	26	-83	-200	-201	-244	-340	-322	-423	-194	-130
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	14.51	25.98	27.88	10.47	21.01	5.21	0.00	6.78	1.96	3.48
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	37.17	91.75	9.71	0.00	18.12	0.00	0.00
Price to Revenue (P/Rev)	5.33	10.42	10.42	10.53	23.06	13.62	0.00	64.79	142.67	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	8.84	16.28	14.62	13.49	29.47	12.58	0.00	13.22	2.44	4.79
Enterprise Value to Revenue (EV/Rev)	5.59	10.67	10.78	10.29	22.74	11.95	0.00	59.75	118.51	0.00
Enterprise Value to EBITDA (EV/EBITDA)	112.59	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	191.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	169.69	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.01	2.42	3.36	1.33	1.39	0.31	0.94	0.49	0.58	0.12
Long-Term Debt to Equity	2.01	2.42	3.19	1.27	1.36	0.31	0.94	0.47	0.43	0.00
Financial Leverage	0.68	0.78	0.11	-0.27	-0.51	-0.59	-0.53	-0.43	-0.35	-0.61
Leverage Ratio	4.41	5.30	3.79	3.02	2.28	2.00	2.04	2.33	2.75	2.38
Compound Leverage Factor	-8.22	8.55	4.41	3.48	2.45	2.05	2.11	2.40	2.80	2.39
Debt to Total Capital	66.78%	70.77%	77.06%	57.05%	58.16%	23.89%	48.41%	32.84%	36.89%	10.64%
Short-Term Debt to Total Capital	0.00%	0.00%	3.99%	2.64%	1.30%	0.00%	0.00%	1.60%	9.83%	10.64%
Long-Term Debt to Total Capital	66.78%	70.77%	73.07%	54.41%	56.86%	23.89%	48.41%	31.25%	27.06%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	33.22%	29.23%	22.94%	42.95%	41.84%	76.11%	51.59%	67.16%	63.11%	89.36%
Debt to EBITDA	14.86	-4.70	-2.07	-2.03	-1.63	-0.44	-1.00	-0.41	-1.09	-0.32
Net Debt to EBITDA	5.34	-1.23	-0.60	0.37	0.35	0.89	0.57	0.44	0.62	1.33
Long-Term Debt to EBITDA	14.86	-4.70	-1.96	-1.94	-1.59	-0.44	-1.00	-0.39	-0.80	0.00
Debt to NOPAT	22.40	-7.18	-2.78	-2.83	-2.30	-0.70	-1.40	-0.56	-1.65	-0.45
Net Debt to NOPAT	8.05	-1.88	-0.81	0.51	0.49	1.42	0.79	0.60	0.94	1.89
Long-Term Debt to NOPAT	22.40	-7.18	-2.64	-2.69	-2.25	-0.70	-1.40	-0.53	-1.21	0.00
Altman Z-Score	-0.75	-0.18	-1.49	-0.15	2.74	0.49	-3.20	1.24	-0.79	0.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.39	2.88	3.05	4.09	4.47	4.04	6.40	5.60	3.06	2.94
Quick Ratio	2.36	2.23	2.59	3.67	4.09	3.77	6.11	5.25	2.99	2.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-55	-73	-158	-176	-201	-226	-224	-236	-151	-341
Operating Cash Flow to CapEx	-953.87%	-928.64%	-46,922.54%	-5,213.47%	-7,229.32%	-1,251.33%	-4,755.15%	-4,721.50%	-2,523.05%	-2,078.87%
Free Cash Flow to Firm to Interest Expense	-1.11	-1.14	-4.26	-5.43	-8.96	-11.95	-9.99	-13.68	-27.95	-215.92
Operating Cash Flow to Interest Expense	-0.68	-1.08	-4.49	-6.24	-10.40	-13.27	-13.39	-12.40	-27.82	-63.46
Operating Cash Flow Less CapEx to Interest Expense	-0.75	-1.19	-4.50	-6.36	-10.55	-14.33	-13.67	-12.66	-28.92	-66.51
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.68	0.53	0.40	0.34	0.30	0.22	0.00	0.04	0.01	0.00
Accounts Receivable Turnover	5.60	5.19	5.54	6.14	6.51	6.60	0.00	6.86	0.00	0.00
Inventory Turnover	0.59	0.89	1.52	1.49	1.85	1.96	0.00	1.55	0.00	0.00
Fixed Asset Turnover	17.31	12.79	8.99	7.08	5.70	6.17	0.00	3.91	0.62	0.00
Accounts Payable Turnover	3.77	2.45	2.09	1.79	1.60	0.43	0.00	0.13	0.02	0.00
Days Sales Outstanding (DSO)	65.20	70.30	65.89	59.49	56.11	55.33	0.00	53.21	0.00	0.00
Days Inventory Outstanding (DIO)	615.23	408.32	239.40	245.55	197.51	186.39	0.00	235.27	0.00	0.00
Days Payable Outstanding (DPO)	96.75	149.29	174.59	204.26	228.01	850.45	0.00	2,777.24	16,042.47	0.00
Cash Conversion Cycle (CCC)	583.68	329.33	130.70	100.78	25.61	-608.73	0.00	-2,488.76	-16,042.47	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	334	262	243	233	201	173	161	167	240	217
Invested Capital Turnover	1.77	1.58	1.38	1.41	1.39	1.09	0.00	0.18	0.02	0.00
Increase / (Decrease) in Invested Capital	72	19	9.73	32	28	13	-6.36	-74	24	249
Enterprise Value (EV)	2,955	4,263	3,550	3,144	5,932	2,179	-182	2,207	588	1,039
Market Capitalization	2,815	4,161	3,430	3,218	6,017	2,482	0.00	2,393	707	1,212
Book Value per Share	$0.65	$0.55	$0.44	$1.10	$1.10	$1.87	$0.00	$2.12	$2.53	$2.78
Tangible Book Value per Share	($0.07)	($0.20)	($0.35)	$0.31	$0.25	$1.00	$0.00	$0.79	($2.28)	($2.70)
Total Capital	584	548	536	716	685	626	665	525	571	389
Total Debt	390	388	413	408	398	150	322	173	211	41
Total Long-Term Debt	390	388	392	389	389	150	322	164	154	0.00
Net Debt	140	102	120	-74	-85	-303	-182	-186	-120	-173
Capital Expenditures (CapEx)	3.55	7.44	0.36	3.88	3.23	20	6.31	4.53	5.95	4.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)	106	29	13	-13	-25	-61	-39	-28	-45	-30
Debt-free Net Working Capital (DFNWC)	356	315	306	470	459	391	465	330	285	184
Net Working Capital (NWC)	356	315	285	451	450	391	465	322	229	143
Net Nonoperating Expense (NNE)	74	98	88	106	104	144	119	-25	73	41
Net Nonoperating Obligations (NNO)	140	102	120	-74	-85	-303	-182	-186	-120	-131
Total Depreciation and Amortization (D&A)	11	10	7.98	8.70	11	7.32	15	13	5.93	1.83
Debt-free, Cash-free Net Working Capital to Revenue	20.08%	7.30%	3.83%	-4.17%	-9.42%	-33.74%	0.00%	-76.46%	-910.55%	0.00%
Debt-free Net Working Capital to Revenue	67.39%	78.97%	93.01%	153.76%	175.82%	214.70%	0.00%	894.46%	5,752.44%	0.00%
Net Working Capital to Revenue	67.39%	78.97%	86.50%	147.57%	172.41%	214.70%	0.00%	871.72%	4,620.92%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.18)	($0.51)	($0.82)	($0.92)	($1.07)	($1.48)	$0.00	($1.85)	($1.49)	($1.20)
Adjusted Weighted Average Basic Shares Outstanding	304.38M	295.16M	289.06M	271.42M	264.32M	257.24M	0.00	186.89M	194.82M	125.21M
Adjusted Diluted Earnings per Share	($0.18)	($0.51)	($0.82)	($0.92)	($1.07)	($1.48)	$0.00	($1.85)	($1.49)	($1.20)
Adjusted Weighted Average Diluted Shares Outstanding	304.38M	295.16M	289.06M	271.42M	264.32M	257.24M	0.00	186.89M	194.82M	125.21M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($1.07)	($1.48)	($1.88)	($1.85)	($1.49)	($1.20)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	300.12M	295.38M	282.71M	280.03M	258.87M	240.42M	185.79M	153.36M	134.40M	109.92M
Normalized Net Operating Profit after Tax (NOPAT)	24	-51	-143	-140	-171	-211	-228	-148	-123	-88
Normalized NOPAT Margin	4.51%	-12.88%	-43.46%	-45.81%	-65.43%	-115.52%	0.00%	-399.72%	-2,471.62%	0.00%
Pre Tax Income Margin	-5.44%	-37.59%	-73.52%	-79.06%	-105.12%	-195.30%	0.00%	-1,216.14%	-4,110.15%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.31	-1.45	-5.60	-6.45	-11.37	-18.40	-15.05	-25.29	-37.05	-83.31
NOPAT to Interest Expense	0.35	-0.84	-4.00	-4.45	-7.71	-11.28	-10.27	-17.95	-23.59	-57.86
EBIT Less CapEx to Interest Expense	0.24	-1.57	-5.61	-6.57	-11.52	-19.46	-15.33	-25.55	-38.15	-86.37
NOPAT Less CapEx to Interest Expense	0.28	-0.96	-4.01	-4.57	-7.85	-12.34	-10.55	-18.21	-24.69	-60.91
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	13.45%	30.09%	36.73%	34.04%	27.97%	30.63%	26.70%	17.06%	9.60%	7.23%	2.70%
EBITDA Growth	83.47%	686.17%	306.43%	152.08%	28.40%	93.89%	43.89%	47.69%	41.31%	15.95%	54.36%
EBIT Growth	77.35%	392.34%	239.47%	137.80%	25.41%	89.63%	34.72%	44.21%	40.32%	15.71%	52.08%
NOPAT Growth	71.31%	1,248.02%	-80.26%	-16,377.37%	26.34%	91.28%	49.70%	68.88%	50.04%	41.33%	20.19%
Net Income Growth	55.21%	143.55%	68.81%	63.69%	8.53%	39.42%	35.18%	30.45%	37.92%	32.92%	33.82%
EPS Growth	56.25%	145.45%	71.43%	66.67%	11.11%	42.11%	41.67%	28.57%	40.00%	34.48%	36.84%
Operating Cash Flow Growth	126.13%	-213.24%	40.10%	240.65%	-64.34%	104.28%	-229.84%	-1.71%	69.01%	-14.55%	50.95%
Free Cash Flow Firm Growth	-2.89%	-98.12%	-33.08%	-3,065.39%	-90.06%	45.23%	-651.19%	-3,317.40%	34.19%	52.22%	122.94%
Invested Capital Growth	19.40%	27.64%	28.97%	3.60%	16.07%	7.81%	30.68%	28.40%	1.79%	4.17%	-16.14%
Revenue Q/Q Growth	-16.34%	5.79%	11.72%	14.73%	-4.07%	11.19%	9.52%	9.54%	-2.07%	7.84%	1.19%
EBITDA Q/Q Growth	-123.49%	-0.12%	51.09%	146.64%	-732.93%	64.83%	61.88%	35.89%	28.95%	-223.11%	64.46%
EBIT Q/Q Growth	-140.06%	0.43%	63.52%	134.42%	-417.20%	52.08%	55.68%	32.09%	28.10%	-201.67%	62.12%
NOPAT Q/Q Growth	-118.76%	238.12%	99.01%	-11,110.39%	-650.84%	78.31%	9.74%	49.89%	11.08%	-25.08%	44.17%
Net Income Q/Q Growth	-247.13%	319.04%	57.13%	67.58%	-43.07%	-56.85%	50.09%	18.33%	5.25%	-67.83%	46.45%
EPS Q/Q Growth	-240.00%	350.00%	60.00%	68.75%	-45.45%	-57.14%	53.33%	16.67%	5.26%	-58.33%	42.86%
Operating Cash Flow Q/Q Growth	298.11%	82.95%	-201.23%	176.41%	-958.73%	109.02%	-137.69%	10.71%	77.63%	-594.75%	26.71%
Free Cash Flow Firm Q/Q Growth	-39.97%	54.09%	95.74%	-3,659.99%	-169.50%	69.16%	-1.30%	-125.76%	22.33%	-410.33%	491.31%
Invested Capital Q/Q Growth	-0.15%	4.91%	21.87%	-6.47%	6.74%	6.00%	-2.10%	4.78%	-0.85%	28.49%	-3.81%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.66%	90.09%	90.62%	91.11%	87.71%	90.16%	90.39%	90.36%	91.95%	89.35%	83.55%
EBITDA Margin	-3.96%	14.10%	14.94%	11.05%	-27.18%	-3.13%	-9.89%	-28.43%	-48.57%	-66.94%	-22.34%
Operating Margin	-6.35%	10.67%	15.30%	11.82%	-25.11%	-3.21%	-16.45%	-19.96%	-43.63%	-48.05%	-41.42%
EBIT Margin	-5.91%	12.34%	13.00%	8.88%	-29.61%	-5.49%	-12.74%	-31.49%	-50.80%	-69.19%	-24.73%
Profit (Net Income) Margin	-17.31%	9.85%	-4.75%	-12.39%	-43.86%	-29.41%	-20.85%	-45.75%	-61.36%	-63.41%	-40.75%
Tax Burden Percent	120.18%	185.77%	-99.17%	-14,534.26%	111.10%	106.90%	87.34%	106.70%	99.46%	79.72%	113.75%
Interest Burden Percent	243.79%	42.94%	36.88%	0.96%	133.33%	500.95%	187.30%	136.14%	121.44%	114.97%	144.82%
Effective Tax Rate	0.00%	-85.77%	199.17%	14,634.26%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-7.87%	35.13%	-26.50%	-3,046.53%	-28.61%	-3.55%	-19.66%	-21.82%	-43.09%	-46.53%	-45.24%
ROIC Less NNEP Spread (ROIC-NNEP)	-19.03%	22.78%	-14.86%	-1,444.45%	-48.83%	-31.78%	-31.02%	-58.49%	-82.14%	-161.66%	-24.99%
Return on Net Nonoperating Assets (RNNOA)	-16.96%	15.55%	-12.07%	-1,595.36%	-60.08%	-24.85%	-19.86%	-33.62%	-32.78%	-17.12%	4.65%
Return on Equity (ROE)	-24.83%	50.69%	-38.57%	-4,641.89%	-88.69%	-28.41%	-39.53%	-55.44%	-75.87%	-63.64%	-40.59%
Cash Return on Invested Capital (CROIC)	-7.49%	-18.44%	-24.01%	-12.66%	-32.98%	-28.94%	-63.80%	-66.25%	-52.92%	-66.48%	-64.18%
Operating Return on Assets (OROA)	-4.25%	8.34%	8.28%	5.47%	-17.63%	-2.92%	-6.23%	-14.43%	-22.40%	-27.96%	-9.32%
Return on Assets (ROA)	-12.44%	6.66%	-3.03%	-7.63%	-26.12%	-15.64%	-10.19%	-20.95%	-27.06%	-25.63%	-15.35%
Return on Common Equity (ROCE)	-24.83%	50.69%	-38.57%	-4,641.89%	-88.69%	-28.41%	-39.53%	-55.44%	-75.87%	-63.64%	-40.59%
Return on Equity Simple (ROE_SIMPLE)	-15.18%	0.00%	-58.54%	-90.20%	-112.53%	0.00%	-130.30%	-166.08%	-199.12%	0.00%	-199.13%
Net Operating Profit after Tax (NOPAT)	-5.57	30	-21	-2,175	-19	-2.58	-12	-13	-26	-30	-24
NOPAT Margin	-4.44%	19.82%	-15.18%	-1,717.34%	-17.58%	-2.25%	-11.51%	-13.97%	-30.54%	-33.63%	-29.00%
Net Nonoperating Expense Percent (NNEP)	11.16%	12.35%	-11.64%	-1,602.08%	20.22%	28.23%	11.35%	36.67%	39.05%	115.14%	-20.25%
Return On Investment Capital (ROIC_SIMPLE)	-0.95%	5.08%	-	-	-	-0.47%	-	-	-	-5.52%	-
Cost of Revenue to Revenue	9.34%	9.91%	9.38%	8.89%	12.29%	9.84%	9.61%	9.64%	8.05%	10.65%	16.45%
SG&A Expenses to Revenue	73.32%	57.89%	53.07%	58.09%	79.73%	61.03%	63.43%	69.23%	85.73%	61.61%	57.87%
R&D to Revenue	22.23%	20.17%	18.49%	19.49%	25.66%	30.44%	39.33%	37.19%	48.10%	72.50%	64.84%
Operating Expenses to Revenue	97.01%	79.42%	75.31%	79.29%	112.82%	93.59%	106.84%	110.31%	135.29%	137.40%	124.98%
Earnings before Interest and Taxes (EBIT)	-7.40	18	18	11	-33	-6.32	-13	-30	-44	-61	-20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.96	21	21	14	-30	-3.60	-10	-27	-42	-59	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	12.65	14.51	17.71	22.17	26.43	25.98	26.20	32.03	30.57	27.88	22.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.51	5.33	6.42	6.45	8.16	10.42	9.38	10.20	9.31	10.42	9.06
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	7.76	8.84	10.38	11.73	12.89	16.28	14.60	14.72	13.59	14.62	15.79
Enterprise Value to Revenue (EV/Rev)	4.77	5.59	6.70	6.73	8.51	10.67	9.68	10.60	9.72	10.78	9.23
Enterprise Value to EBITDA (EV/EBITDA)	50.48	112.59	2,164.48	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	63.58	191.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	82.85	169.69	906.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	726.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.02	2.01	2.18	2.93	2.97	2.42	2.96	3.64	3.95	3.36	3.10
Long-Term Debt to Equity	2.02	2.01	2.18	2.93	2.97	2.42	2.96	3.53	3.83	3.19	2.95
Financial Leverage	0.89	0.68	0.81	1.10	1.23	0.78	0.64	0.57	0.40	0.11	-0.19
Leverage Ratio	4.66	4.41	4.97	6.06	6.10	5.30	5.73	5.37	4.48	3.79	3.37
Compound Leverage Factor	11.37	1.89	1.83	0.06	8.13	26.57	10.74	7.31	5.44	4.35	4.88
Debt to Total Capital	66.87%	66.78%	68.53%	74.59%	74.82%	70.77%	74.73%	78.46%	79.80%	77.06%	75.62%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.51%	2.49%	3.99%	3.65%
Long-Term Debt to Total Capital	66.87%	66.78%	68.53%	74.59%	74.82%	70.77%	74.73%	75.95%	77.31%	73.07%	71.97%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	33.13%	33.22%	31.47%	25.41%	25.18%	29.23%	25.27%	21.54%	20.20%	22.94%	24.38%
Debt to EBITDA	7.62	14.86	254.90	-13.03	-5.49	-4.70	-2.86	-2.78	-2.38	-2.07	-1.95
Net Debt to EBITDA	2.73	5.34	91.45	-4.32	-2.10	-1.23	-0.82	-0.96	-0.81	-0.60	-0.27
Long-Term Debt to EBITDA	7.62	14.86	254.90	-13.03	-5.49	-4.70	-2.86	-2.69	-2.30	-1.96	-1.85
Debt to NOPAT	12.50	22.40	106.74	-16.60	-8.24	-7.18	-4.86	-4.38	-3.32	-2.78	-2.43
Net Debt to NOPAT	4.48	8.05	38.29	-5.50	-3.16	-1.88	-1.40	-1.52	-1.13	-0.81	-0.33
Long-Term Debt to NOPAT	12.50	22.40	106.74	-16.60	-8.24	-7.18	-4.86	-4.24	-3.22	-2.64	-2.31
Altman Z-Score	-1.23	-0.73	-0.55	-1.15	-0.88	0.18	-0.64	-0.78	-1.30	-0.82	-0.96
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.34	3.39	3.15	2.75	3.03	2.88	2.73	2.72	2.89	3.05	2.78
Quick Ratio	2.22	2.36	2.20	2.05	2.22	2.23	2.09	2.07	2.42	2.59	2.47
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-60	-43	-93	-2,184	-58	-22	-70	-69	-31	-39	13
Operating Cash Flow to CapEx	3,659.43%	-1,359.72%	-6,452.53%	2,066.58%	-1,639.70%	199.77%	-2,450.29%	-732.65%	-930.43%	-3,017.26%	0.00%
Free Cash Flow to Firm to Interest Expense	-5.22	-3.57	-7.33	-174.59	-4.67	-0.81	-5.38	-5.52	-2.58	-3.55	1.32
Operating Cash Flow to Interest Expense	0.68	-0.33	-1.81	1.81	-2.39	0.13	-2.95	-1.29	-1.53	-7.28	-1.21
Operating Cash Flow Less CapEx to Interest Expense	0.66	-0.35	-1.84	1.73	-2.53	0.06	-3.07	-1.47	-1.69	-7.52	-1.19
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.72	0.68	0.64	0.62	0.60	0.53	0.49	0.46	0.44	0.40	0.38
Accounts Receivable Turnover	6.59	5.60	5.76	6.12	5.86	5.19	5.93	6.03	5.59	5.54	6.23
Inventory Turnover	0.53	0.59	0.57	0.69	1.00	0.89	1.01	1.08	1.48	1.52	2.10
Fixed Asset Turnover	17.77	17.31	16.05	14.84	13.27	12.79	11.72	10.97	10.21	8.99	8.69
Accounts Payable Turnover	4.32	3.77	2.70	2.02	2.57	2.45	2.01	2.12	1.59	2.09	2.03
Days Sales Outstanding (DSO)	55.36	65.20	63.36	59.63	62.32	70.30	61.57	60.53	65.35	65.89	58.56
Days Inventory Outstanding (DIO)	690.25	615.23	636.04	525.36	364.42	408.32	362.09	339.22	246.78	239.40	174.02
Days Payable Outstanding (DPO)	84.55	96.75	135.26	180.45	141.91	149.29	181.54	171.98	230.19	174.59	179.81
Cash Conversion Cycle (CCC)	661.06	583.68	564.15	404.55	284.84	329.33	242.12	227.77	81.93	130.70	52.77
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	334	334	319	261	279	262	247	252	241	243	189
Invested Capital Turnover	1.77	1.77	1.75	1.77	1.63	1.58	1.71	1.56	1.41	1.38	1.56
Increase / (Decrease) in Invested Capital	54	72	72	9.09	39	19	58	56	4.22	9.73	-36
Enterprise Value (EV)	2,589	2,955	3,307	3,067	3,603	4,263	3,605	3,715	3,274	3,550	2,985
Market Capitalization	2,449	2,815	3,168	2,938	3,454	4,161	3,491	3,574	3,135	3,430	2,928
Book Value per Share	$0.64	$0.65	$0.60	$0.45	$0.43	$0.55	$0.46	$0.39	$0.36	$0.44	$0.47
Tangible Book Value per Share	($0.07)	($0.07)	($0.12)	($0.28)	($0.29)	($0.20)	($0.30)	($0.38)	($0.42)	($0.35)	($0.31)
Total Capital	584	584	568	521	519	548	527	518	508	536	544
Total Debt	391	390	389	389	388	388	394	406	405	413	411
Total Long-Term Debt	391	390	389	389	388	388	394	393	393	392	391
Net Debt	140	140	140	129	149	102	114	141	138	120	56
Capital Expenditures (CapEx)	0.21	0.29	0.36	1.10	1.81	1.73	1.57	2.20	1.94	2.68	-0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	107	106	91	34	50	29	14	21	6.87	13	-41
Debt-free Net Working Capital (DFNWC)	358	356	340	294	289	315	294	287	274	306	314
Net Working Capital (NWC)	358	356	340	294	289	315	294	274	261	285	294
Net Nonoperating Expense (NNE)	16	15	-15	-2,160	29	31	9.66	30	27	26	9.60
Net Nonoperating Obligations (NNO)	140	140	140	129	149	102	114	141	138	120	56
Total Depreciation and Amortization (D&A)	2.44	2.64	2.74	2.74	2.69	2.72	2.95	2.90	1.92	1.98	1.95
Debt-free, Cash-free Net Working Capital to Revenue	19.76%	20.08%	18.35%	7.37%	11.70%	7.30%	3.63%	5.98%	2.04%	3.83%	-12.68%
Debt-free Net Working Capital to Revenue	65.90%	67.39%	68.94%	64.44%	68.28%	78.97%	78.90%	81.75%	81.35%	93.01%	97.04%
Net Working Capital to Revenue	65.90%	67.39%	68.94%	64.44%	68.28%	78.97%	78.90%	78.04%	77.59%	86.50%	90.91%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.07)	$0.05	($0.02)	($0.05)	($0.16)	($0.11)	($0.07)	($0.15)	($0.18)	($0.19)	($0.12)
Adjusted Weighted Average Basic Shares Outstanding	307.69M	304.38M	304.69M	303.77M	302.90M	295.16M	295.76M	292.80M	291.34M	289.06M	289.22M
Adjusted Diluted Earnings per Share	($0.07)	$0.05	($0.02)	($0.05)	($0.16)	($0.11)	($0.07)	($0.15)	($0.18)	($0.19)	($0.12)
Adjusted Weighted Average Diluted Shares Outstanding	307.69M	304.38M	304.69M	303.77M	302.90M	295.16M	295.76M	292.80M	291.34M	289.06M	289.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	307.93M	300.12M	298.81M	296.59M	296.20M	295.38M	293.25M	287.12M	284.58M	282.71M	280.95M
Normalized Net Operating Profit after Tax (NOPAT)	-5.57	11	17	10	-15	-2.58	-11	-12	-26	-29	-23
Normalized NOPAT Margin	-4.44%	7.47%	12.27%	8.27%	-13.74%	-2.25%	-10.16%	-12.88%	-30.54%	-32.37%	-28.51%
Pre Tax Income Margin	-14.41%	5.30%	4.79%	0.09%	-39.48%	-27.51%	-23.87%	-42.87%	-61.69%	-79.55%	-35.82%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.65	1.55	1.45	0.90	-2.63	-0.24	-1.02	-2.38	-3.70	-5.49	-2.10
NOPAT to Interest Expense	-0.49	2.48	-1.69	-173.86	-1.56	-0.10	-0.92	-1.06	-2.22	-2.67	-2.46
EBIT Less CapEx to Interest Expense	-0.66	1.52	1.42	0.81	-2.77	-0.30	-1.14	-2.56	-3.86	-5.74	-2.09
NOPAT Less CapEx to Interest Expense	-0.50	2.46	-1.72	-173.95	-1.71	-0.16	-1.04	-1.23	-2.39	-2.91	-2.45
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Amicus Therapeutics' Financials

When does Amicus Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Amicus Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amicus Therapeutics' net income changed over the last 8 years?

Amicus Therapeutics' net income appears to be on a downward trend, with a most recent value of -$56.11 million in 2024, falling from -$132.12 million in 2015. The previous period was -$151.58 million in 2023. Check out Amicus Therapeutics' forecast to explore projected trends and price targets.

What is Amicus Therapeutics's operating income?

Amicus Therapeutics's total operating income in 2024 was $24.88 million, based on the following breakdown:

Total Gross Profit: $475.35 million
Total Operating Expenses: $450.48 million

How has Amicus Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Amicus Therapeutics' total revenue changed from $0.00 in 2015 to $528.30 million in 2024, a change of 52,829,500,000.0%.

How much debt does Amicus Therapeutics have?

Amicus Therapeutics' total liabilities were at $590.99 million at the end of 2024, a 4.3% decrease from 2023, and a 5.4% increase since 2015.

How much cash does Amicus Therapeutics have?

In the past 9 years, Amicus Therapeutics' cash and equivalents has ranged from $49.06 million in 2017 to $246.99 million in 2023, and is currently $213.75 million as of their latest financial filing in 2024.

How has Amicus Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Amicus Therapeutics' book value per share changed from 2.78 in 2015 to 0.65 in 2024, a change of -76.7%.

Related Companies

This page (NASDAQ:FOLD) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amicus Therapeutics (FOLD) Financials

Frequently Asked Questions About Amicus Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amicus Therapeutics (FOLD) Financials

Annual Income Statements for Amicus Therapeutics

Quarterly Income Statements for Amicus Therapeutics

Annual Cash Flow Statements for Amicus Therapeutics

Quarterly Cash Flow Statements for Amicus Therapeutics

Annual Balance Sheets for Amicus Therapeutics

Quarterly Balance Sheets for Amicus Therapeutics

Annual Metrics And Ratios for Amicus Therapeutics

Quarterly Metrics And Ratios for Amicus Therapeutics

Frequently Asked Questions About Amicus Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools